Compare ASMB & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASMB | PDSB |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 553.6M | 49.2M |
| IPO Year | 2010 | N/A |
| Metric | ASMB | PDSB |
|---|---|---|
| Price | $33.80 | $0.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $43.40 | $9.00 |
| AVG Volume (30 Days) | 138.9K | ★ 587.9K |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,191,000.00 | N/A |
| Revenue This Year | $33.33 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 31.30 | N/A |
| 52 Week Low | $7.75 | $0.70 |
| 52 Week High | $39.71 | $2.20 |
| Indicator | ASMB | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 48.81 | 50.13 |
| Support Level | $31.51 | $0.86 |
| Resistance Level | $38.99 | $0.93 |
| Average True Range (ATR) | 2.15 | 0.07 |
| MACD | -0.32 | -0.00 |
| Stochastic Oscillator | 33.29 | 19.98 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.